Psoriasis drug study looks at immune marker IL-33
NCT ID NCT07557095
First seen May 02, 2026 · Last updated May 17, 2026 · Updated 5 times
Summary
This study compares two common psoriasis drugs, cyclosporine and methotrexate, to see how they affect a protein called IL-33 in the blood. Researchers will measure IL-33 levels and skin severity in 118 adults with moderate to severe psoriasis. The goal is to understand how these treatments work, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGYPTIAN PSORIATIC PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.